Search results
23 mar 2022 · A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses of the BNT162b2 vaccine...
- Review Article Brain Tumors in Children A.R. Cohen
Brain tumors are the most common solid neoplasms and the...
- Images in Clinical Medicine Syphilitic Aortitis S.A. Miller and E.R. Ladich
A 61-year-old man presented with a 2-day history of left...
- Editorial Childhood Risk Factors and Prediction of Adult Cardiovascular End Points J.R. Ingelfinger
This editorial was published on April 4, 2022, at NEJM.org....
- Images in Clinical Medicine Gaucher's Disease L. Suner and F. Delhommeau
Rapid and long‐lasting efficacy of high‐dose ambroxol...
- Perspective Progress Toward Pig-to-Human Xenotransplantation R.N. Pierson, III
In light of the recent clinical cases of pig-to-human kidney...
- Perspective Reforming Nursing Home Financing, Payment, and Oversight R.M. Werner and Others
More than 30 years after the Nursing Home Reform Act, the...
- Editorial Audio Interview
In this audio interview conducted on May 17, 2022, the...
- Free Full Text
Among participants with and those without evidence of prior...
- Review Article Brain Tumors in Children A.R. Cohen
24 paź 2024 · U większości podaje się 1 dawkę przypominającą, po upływie min. 3 miesięcy od podania poprzedniej dawki szczepienia przeciwko COVID-19. Jedynie u dzieci w wieku od 6 miesięcy do 4 lat, które nie chorowały wcześniej na COVID-19 i nie były przeciwko tej chorobie szczepione, rekomendowane jest podanie szczepienia w 3-dawkowym ...
4 gru 2021 · Our findings suggest that a third dose of the BNT162b2 mRNA vaccine is effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least 5 months ago.
14 sty 2022 · The BNT162b2 and mRNA-1273 booster doses were combined in the 0- to 1-day and 2- to 6-day postbooster periods. Subsequent periods (7–13, 14–34, 35–69 and ≥70 days) were analyzed...
24 lip 2023 · When a heterologous booster schedule was compared with the homologous booster schedule, vaccine effectiveness was 27.2% (3.7% to 50.6%) for AZD1222+BNT162b2 or mRNA-1273 and 23.3% (15.8% to 30.8%) for BNT162b2+mRNA-1273 schedules against covid-19 related hospital admission and 21.7% (−8.3% to 51.7%) and 18.4% (−15.7% to 52.5%) against death ...
6 kwi 2022 · The results showed a 2-times lower rate of confirmed infection and a 3.5-times lower rate of severe COVID-19 in adults in this age group in the fourth week after receiving a fourth dose compared to adults who received a third dose more than four months before.
1 kwi 2022 · This study found that although third-dose vaccination against SARS-CoV-2 infection was associated with increased reporting of low-severity adverse events, risk of severe adverse events remained comparable with risk associated with the standard 2-dose regime.
